No Data
No Data
Chongqing Sansheng Industrial: 2024 Interim Performance Forecast
Chongqing SanSheng Industrial (002742.SZ): expects a pre-tax loss of RMB 65-80 million in the first half of the year.
Chongqing Sansheng Industrial (002742.SZ) announced its performance forecast for the first half of 2024. The net income attributable to shareholders of the listed company during the reporting period is expected to be a loss of 65-80 million yuan, compared to a loss of 97.5204 million yuan in the same period of last year. The net income after deducting non-recurring gains and losses is expected to be a loss of 47-64 million yuan, compared to a loss of 103.1736 million yuan in the same period of last year. The operating income is expected to be 750-800 million yuan. The main reason for the loss in performance in the first half of 2024 is due to the impact of downstream real estate industry, and the performance of the building materials sector has declined. Debt.
Chongqing Sansheng Industrial (002742.SZ): overseas subsidiary received a letter from banks.
On June 6th, Gelunhui reported that Chongqing Sansheng Industrial (002742.SZ) announced that its overseas subsidiary, Sansheng Pharmaceutical Co., Ltd., signed a mortgage guarantee contract with the Ethiopian NIB International Bank on June 26, 2019, providing guarantees for SSC Construction P.L.C (referred to as "SSC") to borrow 400 million birr (approximately RMB 51.83 million) from NIB Bank using its plant and machinery equipment as collateral. This matter constituted the company's violation of providing guarantees to external parties without the approval of the board of directors, supervisory board, and shareholders' meeting. As of 202
Chongqing Sansheng Industrial Co.,Ltd. (SZSE:002742) Looks Inexpensive After Falling 40% But Perhaps Not Attractive Enough
ST Sansheng (002742.SZ): The company's pharmaceutical products do not involve synthetic biology
Gelonghui, May 15 | ST Sansheng (002742.SZ) said on the investor interactive platform that the company's pharmaceutical products do not involve synthetic biology.
ST Sansheng (002742.SZ) received a decision on corrective measures ordered by the Chongqing Securities Regulatory Bureau
Zhitong Finance App News, ST Sansheng (002742.SZ) announced that the company received the “Decision on Administrative Supervision Measures” issued by the China Securities Regulatory Commission and the Chongqing Securities Regulatory Bureau on May 10, 2024. The Chongqing Securities Regulatory Bureau decided to take corrective administrative supervision measures against the company and Pan Xianwen. According to the announcement, according to Chapter 9, Section 4 of the “Shenzhen Stock Exchange Stock Listing Rules (2024 Revision)”, if the company fails to clear 113 million yuan of occupied capital and interest within six months in accordance with the requirements of the ordered corrective measures, the Shenzhen Stock Exchange will suspend trading of the company's shares, and not within two months after the suspension
No Data